Introduction
Idoven is a Madrid digital health company founded in 2018 that builds Willem — an artificial intelligence platform analyzing electrocardiograms to detect cardiovascular disease patterns often missed in clinical review. Dr. Manuel Marina Breysse, a cardiologist, co-founded Idoven and serves as chief executive officer per the company team page reviewed in July 2026. Idoven’s mission statement on its about page frames AI in healthcare as transformational specifically against cardiovascular disease — the leading global killer — by combining medical expertise, engineering, and machine learning on ECG signals locked in proprietary legacy formats.
On May 28, 2025, Idoven and AstraZeneca announced CONCERTO — a project developing and validating tailored AI on Willem to detect transthyretin amyloidosis from ECG analysis, addressing diagnostic journeys that can take up to four years per quoted clinician leaders in the official blog post.
What the company does
Willem ingests ECG data from diverse device formats, applies deep learning models trained on large annotated cohorts, and surfaces patterns suggestive of cardiac conditions including amyloidosis, atrial fibrillation, and heart failure precursors. The May 2025 CONCERTO announcement describes models trained on thousands of ECGs from confirmed amyloidosis patients entering external validation at European hospitals in Spain, France, and Italy — a pharma-co-funded pathway Idoven uses to reach rare-disease detection without waiting for symptomatic specialist referrals.
Idoven’s 2024 regulatory timeline cites Willem CE Mark Class IIa with the broadest device-approved scope on the market covering 22 cardiac patterns — regulatory breadth MedTech partners need when embedding Idoven AI into implantable cardiac monitors and screening programs beyond single-indication pilots.
Who it serves
Idoven serves pharmaceutical cardiac therapeutic programs — AstraZeneca CONCERTO and FAITHFUL heart-failure consortia appear on the about timeline — MedTech ECG device manufacturers including Abbott collaboration on implantable monitor episode classification, and hospital preventative screening initiatives. Marina Breysse quotes in the CONCERTO post emphasize physicians gaining AI tools for earlier identification and timely treatment access — language rare-disease pharma medical affairs teams use when funding diagnostic enablement ahead of therapy launches.
Life sciences buyers evaluate Idoven on external validation rigor and CE-marked scope; hospital buyers evaluate integration with existing ECG carts and remote monitoring workflows.
Company background
Marina Breysse co-founded Idoven in 2018 with chief scientific officer José María Lillo, translating a decade of cardiology and AI research into commercial Willem deployments. The about page chronicles Google and Santander partnerships in 2019, EU Seal of Excellence awards, €18.5 million Series A in 2022 co-led by Insight Partners and Northzone, and CB Insights Digital Health 50 recognition — funding and analyst visibility supporting enterprise pharma contracts like CONCERTO.
Brand ambassadors Iker Casillas and Pau Gasol appear in Idoven marketing materials, reflecting Spanish market visibility strategies alongside clinical validation publications.
Product and AI capabilities
CONCERTO’s amyloidosis model targets ATTR systemic disease where protein deposits mimic common heart failure symptoms — 34% to 57% initial misdiagnosis rates cited in the May 2025 post illustrate economic and clinical harm from delayed specialty workups. ECG-first screening leverages ubiquitous, low-cost data capture relative to nuclear scintigraphy confirmatory pathways — an access argument Idoven makes for health systems that already record millions of ECGs annually without mining them for rare disease signals.
Peer-reviewed 2026 materials on the about timeline cite 96.4% AUC 0.88 for AI-based cardiac amyloidosis detection from 12-lead ECGs — metrics pharma partners require before embedding Willem into pre-initiation ECG testing programs.
Key developments
2018: Idoven founded in Madrid by Manuel Marina Breysse. 2022: €18.5M Series A; Abbott ICM collaboration begins. 2024: Willem CE Mark Class IIa for 22 patterns; FAITHFUL heart-failure consortium with AstraZeneca. May 28, 2025: CONCERTO amyloidosis project announced (official source). 2026: AlumniXXI EmprendeXXI award and continued CONCERTO validation cited on news index.
Why it matters
Idoven matters because ECG AI is shifting from arrhythmia detection into rare cardiomyopathy screening bundled with pharma disease-awareness budgets — CONCERTO is a concrete 2025 example. Marina Breysse’s clinician-founder credibility addresses cardiologist skepticism that pure-tech vendors cannot navigate guideline pathways. Compare with Tricog Health cloud ECG STEMI networks and Quibim MRI oncology AI — Idoven owns ambulatory and 12-lead ECG intelligence for cardiovascular pharma endpoints.
Sector context
Idoven belongs in Brel’s AI in healthcare coverage under digital health and cardiovascular AI. Distinct from thoracic imaging vendors in this batch — ECG AI scales through device OEM partnerships and pharma screening economics. Buyers should verify Willem’s cleared pattern list per market and separate research algorithms from device-labelled indications during contract scoping.
Sources and references
Idoven CONCERTO blog post (May 28, 2025) and Our team page with Manuel Marina Breysse.
- Idoven — CONCERTO with AstraZeneca (idoven.ai, May 28, 2025)
- Idoven — Our team (idoven.ai)
Reviewed July 10, 2026. Manuel Marina Breysse is cardiologist, CEO, and co-founder. Founded 2018 in Madrid. Confidence: High.